Post by Exploration of Targeted Anti-tumor Therapy

🔥Well-Performing Review This published review has gained robust reads, reflecting high community interest in evolving EGFR-mutant NSCLC treatment strategies. The work systematically outlines current first-line and subsequent therapies for EGFR-mutant NSCLC, evaluating treatment efficacy, acquired resistance mechanisms, and clinical tolerability. It particularly highlights antibody-drug conjugates (ADCs) as a promising solution to overcome therapeutic resistance, offering valuable insights for refractory EGFR-mutant NSCLC management. As a well-received precision oncology resource, this review delivers practical, up-to-date evidence to optimize sequential treatment for EGFR-mutant NSCLC patients. 1️⃣Title: The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability 2️⃣ URL: https://lnkd.in/gpZWw5aC 3️⃣ Authors: Carminia Maria Della Corte, Caterina De Rosa, Faiz Ul Haq, Floriana Morgillo #EGFRmutantNSCLC #PrecisionOncology #AcquiredResistance #ADCs #LungCancer #ClinicalResearch #OncologyReview